ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Medivation, Inc." (MDVN) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Medivation, Inc." (MDVN)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: ANAC, RGEN, CBPO, LJPC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Medivation, Inc."© quotemedia

Company Profile

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule, which is in Phase-III development for the treatment of castration-resistant prostate cancer. Medivation, Inc. has collaboration with Astellas for the development, manufacture, and commercialization of MDV3100 for the treatment of prostate cancer. The company was founded in 2003 and is headquartered in San Francisco, California.

Recent News: "Medivation, Inc."